Avantor Performance Materials Names New CEO
PTSM: Pharmaceutical Technology Sourcing and Management
Avantor Performance Materials appoints Michael Stubblefield as CEO.
Avantor Performance Materials, a manufacturer and supplier of high-performance chemistries, reported the appointment of Michael Stubblefield as CEO. Stubblefield has over 20 years of global chemical industry leadership experience. Most recently, Stubblefield served as a senior expert for the Chemicals Practice of McKinsey & Company.
In his role as CEO, Stubblefield will oversee all aspects of Avantor’s global operations in its four business areas, which include laboratory products, pharmaceuticals, electronic materials, and diagnostics. He will be based at Avantor’s corporate headquarters in Center Valley, PA. Stubblefield holds an MBA from Texas A&M University-Corpus Christi, and a Bachelor of Science degree in chemical engineering from the University of Utah.
Source: Avantor Performance Materials
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
